16.54

5.55% 0.87

After Hours: 16.01 -0.53 -3.20%

Atrium Therapeutics Inc (RNA)

Overview News Price History Option Chain Financials Discussions Forecast

Atrium Therapeutics Inc stock is traded at $16.54, with a volume of 2.00M. It is up +5.55% in the last 24 hours and down -77.26% over the past month. Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Previous Close:

$15.67

Open:

$15.32

24h Volume:

2.00M

Relative Volume:

0.82

Market Cap:

$2.56B

Revenue:

$10.73M

Net Income/Loss:

$-455.74M

P/E Ratio:

-4.6501

EPS:

-3.5569

Net Cash Flow:

$-502.70M

1W Performance:

-77.28%

1M Performance:

-77.26%

6M Performance:

-65.88%

1Y Performance:

-42.09%

1-Day Range:

$15.32

$16.57

1-Week Range:

$13.06

$16.57

52-Week Range:

$13.06

$73.06

Atrium Therapeutics Inc Stock (RNA) Company Profile

Name

Atrium Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (621)

Phone

858-401-7900

Address

3020 CALLAN ROAD, SAN DIEGO, CA

Employee

391

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

RNA's Discussions on Twitter

Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNA Atrium Therapeutics Inc	16.54	2.42B	10.73M	-455.74M	-502.70M	-3.5569
VRTX Vertex Pharmaceuticals Inc	477.89	120.48B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	787.50	81.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	749.56	46.33B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	327.30	42.26B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.02	32.87B	5.36B	287.73M	924.18M	2.5229

Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-17-25	Initiated	Roth Capital	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Bernstein	Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Jun-11-25	Initiated	Raymond James	Strong Buy
Mar-13-25	Initiated	Citigroup	Buy
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-20-24	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Sep-24-24	Initiated	Goldman	Buy
Aug-28-24	Initiated	Barclays	Overweight
May-03-24	Initiated	BofA Securities	Buy
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight
May-22-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Strong Buy
Sep-07-21	Initiated	Evercore ISI	Outperform
Jun-17-21	Initiated	Needham	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Wells Fargo	Overweight

View All

Atrium Therapeutics Inc Stock (RNA) Latest News

Mar 02, 2026

Atrium Therapeutics Inc. share price - Capital.com

Mar 02, 2026

Atrium Tx launches with Avidity's RNA ticker and cardio assets - BioWorld MedTech

Mar 02, 2026